» Articles » PMID: 30135583

A Multi-cohort Study of the Immune Factors Associated with M. Tuberculosis Infection Outcomes

Abstract

Most infections with Mycobacterium tuberculosis (Mtb) manifest as a clinically asymptomatic, contained state, known as latent tuberculosis infection, that affects approximately one-quarter of the global population. Although fewer than one in ten individuals eventually progress to active disease, tuberculosis is a leading cause of death from infectious disease worldwide. Despite intense efforts, immune factors that influence the infection outcomes remain poorly defined. Here we used integrated analyses of multiple cohorts to identify stage-specific host responses to Mtb infection. First, using high-dimensional mass cytometry analyses and functional assays of a cohort of South African adolescents, we show that latent tuberculosis is associated with enhanced cytotoxic responses, which are mostly mediated by CD16 (also known as FcγRIIIa) and natural killer cells, and continuous inflammation coupled with immune deviations in both T and B cell compartments. Next, using cell-type deconvolution of transcriptomic data from several cohorts of different ages, genetic backgrounds, geographical locations and infection stages, we show that although deviations in peripheral B and T cell compartments generally start at latency, they are heterogeneous across cohorts. However, an increase in the abundance of circulating natural killer cells in tuberculosis latency, with a corresponding decrease during active disease and a return to baseline levels upon clinical cure are features that are common to all cohorts. Furthermore, by analysing three longitudinal cohorts, we find that changes in peripheral levels of natural killer cells can inform disease progression and treatment responses, and inversely correlate with the inflammatory state of the lungs of patients with active tuberculosis. Together, our findings offer crucial insights into the underlying pathophysiology of tuberculosis latency, and identify factors that may influence infection outcomes.

Citing Articles

Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the Infectious Diseases Working Party of the EBMT.

Drozd-Sokolowska J, Tridello G, Verheggen I, Karakukcu M, Ben Abdeljelil N, Colita A Bone Marrow Transplant. 2025; .

PMID: 39994334 DOI: 10.1038/s41409-025-02530-4.


Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents.

Picchianti-Diamanti A, Aiello A, De Lorenzo C, Migliori G, Goletti D Front Immunol. 2025; 16:1494283.

PMID: 39963138 PMC: 11830708. DOI: 10.3389/fimmu.2025.1494283.


Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes.

Simonson A, Zeppa J, Bucsan A, Chao M, Pokkali S, Hopkins F J Exp Med. 2025; 222(4).

PMID: 39912921 PMC: 11801270. DOI: 10.1084/jem.20241571.


Humoral correlates of protection against following intravenous BCG vaccination in rhesus macaques.

Irvine E, Darrah P, Wang S, Wang C, McNamara R, Roederer M iScience. 2024; 27(12):111128.

PMID: 39669431 PMC: 11634979. DOI: 10.1016/j.isci.2024.111128.


Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders.

Toh J, Reitsma A, Tajima T, Younes S, Ezeiruaku C, Jenkins K Cell Rep Med. 2024; 5(12):101851.

PMID: 39657667 PMC: 11722118. DOI: 10.1016/j.xcrm.2024.101851.


References
1.
Scholkopf , Smola , Williamson , Bartlett . New support vector algorithms. Neural Comput. 2000; 12(5):1207-45. DOI: 10.1162/089976600300015565. View

2.
Junqueira-Kipnis A, Kipnis A, Jamieson A, Gonzalez Juarrero M, Diefenbach A, Raulet D . NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol. 2003; 171(11):6039-45. DOI: 10.4049/jimmunol.171.11.6039. View

3.
Ueda Y, Kondo M, Kelsoe G . Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med. 2005; 201(11):1771-80. PMC: 1952536. DOI: 10.1084/jem.20041419. View

4.
Shih C, van Eeden S, Goto Y, Hogg J . CCL23/myeloid progenitor inhibitory factor-1 inhibits production and release of polymorphonuclear leukocytes and monocytes from the bone marrow. Exp Hematol. 2005; 33(10):1101-8. DOI: 10.1016/j.exphem.2005.06.028. View

5.
Ruvinsky I, Meyuhas O . Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci. 2006; 31(6):342-8. DOI: 10.1016/j.tibs.2006.04.003. View